Field evaluation of PIMA point-of-care CD4 testing in Rakai, Uganda

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Galiwango, Ronald M ^a   Lubyayi, Lawrence ^a   Musoke, Richard ^a   Kalibbala, Sarah ^a   Buwembo, Martin ^a   Kasule, Jjingo ^a   Serwadda, David ^e   Gray, Ronald H ^b   Reynolds, Steven J ^c,d   Chang, Larry W ^d  

^a RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4 T CELL COUNT TEST; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UGANDA; VERY ELDERLY; DEVICES; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFORMATION SYSTEM; PROCEDURES; REFERENCE VALUE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FLOW CYTOMETRY; HUMANS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; UGANDA;

EID: 84897520378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088928     Document Type: Article

References (18)

1. Kagaayi J, Makumbi F, Nakigozi G, Wawer MJ, Gray RH, et al. (2007) WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda. AIDS 21(9): p. 1208-10. (Pubitemid 46763293)
2. Jaffar S, Birungi J, Grosskurth H, Amuron B, Namara G, et al. (2008) Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. AIDS Res Ther. 5:4
3. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, et al. (2005). Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19(18): p. 2141-8. (Pubitemid 41669003)
4. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis, 43(6): p. 770-6. (Pubitemid 44330743)
5. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, et al. (2009) Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med, 6(4): p. e1000066.
6. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA, 296(7): p. 782-93. (Pubitemid 44223102)
7. Manabe YC, Wang Y, Elbireer A, Auerbach B, Castelnuovo B. (2012) Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS One, 7(4): p. e34319.
8. Mnyani, C.N., McIntyre, J.A. and Myer L. (2012) The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy. J Acquir Immune Defic Syndr, 60(3): p. 260-4.
9. Diaw PA, Daneau G, Coly AA, Ndiaye BP, Wade D, et al. Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr. 58(4): p. e103-11.
10. Herbert S, Edwards S, Carrick G, Copas A, Sandford C, et al. (2012) Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service. Sex Transm Infect, 88(6): p. 413-7.
11. Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, et al. (2011) Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS, 25(6): p. 807-12.
12. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, et al. (2010) Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr, 55(1): p. 1-7.
13. Glencross DK, Coetzee LM, Faal M, Masango M, Stevens WS, et al. (2012) Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc, 15(1): p. 3.
14. Kiwanuka N, Robb M, Kigozi G, Birx D, Philips J, et al. (2004) Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: a population-based study, Rakai, Uganda. J Acquir Immune Defic Syndr, 36(2): p. 721-5. (Pubitemid 38685966)
15. Alere website, Alere Pima CD4 Customer Training - http://www.alere.co.uk/ sexual-health/articles/alere-pimatm-cd4-customer-training-241/text.htm, Alere. Accessed 2013 October 12.
16. Bland, J.M. and Altman D.G. (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1(8476): p. 307-10. (Pubitemid 16134762)
17. Mwau M, Adungo F, Kadima S, Njagi E, Kirwaye C, et al. (2013) Evaluation of PIMA(R) point of care technology for CD4 T cell enumeration in Kenya. PLoS One. 8(6): p. e67612.
18. Thakar M, Mahajan B, Shaikh N, Bagwan S, Sane S, et al. (2012) Utility of the point of care CD4 analyzer, PIMA, to enumerate CD4 counts in the field settings in India. AIDS Res Ther. 9(1): p. 26.